Search Results
Your search for what matches 6297 pages
Showing 651 - 700Benjamin Besse, MD, PhD, Chooses a Career in Medicine Over Music
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Benjamin Besse, MD, PhD, Professor of Medical Oncology at Paris-Saclay University, Orsay, France, and lung cancer specialist at Gustave Roussy Cancer Campus, Villejuif. Currently, Dr....
There’s an App for That: Digital Health Solutions for Treating Insomnia in Cancer Survivors
Guest Editor’s Note: Insomnia is common in patients with cancer and cancer survivors, and it has significant negative consequences. Cognitive behavior therapy for insomnia (CBT-I) is an effective approach for managing insomnia but is not easily available to many patients. In this installment of The ...
Expert Point of View: Martina C. Murphy, MD
Discussant of the ENGOT-EN5/GOG-305/SIENDO trial, Martina C. Murphy, MD, Associate Professor of the Department of Medicine, Division of Hematology, University of Florida, shared insights on the topic of maintenance therapy, its effects on quality of life, and toxicity management. Dr. Murphy...
ASCO Participates in President’s Cancer Panel Event
ASCO joined the President’s Cancer Panel on September 7, 2023, to highlight the numerous ways ASCO is working to advance the National Cancer Plan and achieve President Biden’s Cancer Moonshot goal of “ending cancer as we know it.” This all-day, virtual event was the first public meeting in support...
23andMe Granted FDA 510(k) Clearance to Report Additional BRCA Variants
23andMe has announced that the company has received a U.S. Food and Drug Administration (FDA) 510(k) clearance to expand its existing BRCA1/BRCA2 (Selected Variants) Genetic Health Risk Report. The clearance allows 23andMe to report an additional 41 variants in the BRCA1 and BRCA2 genes known to be ...
Statins May Be Linked to Lower Risk of Colorectal Cancer in Patients With Ulcerative Colitis
Cholesterol-lowering statins may reduce colorectal cancer incidence and mortality in patients with ulcerative colitis, according to a recent study published by Sun et al in eClinicalMedicine. The findings also suggested that statin use may be associated with a lower risk of all-cause mortality in...
How Is Administrative Payment Burden Associated With Cost-Related Delays in Cancer Care?
Research shows that the United States’ health-care delivery and financing system is so complex that streamlining administrative costs alone could reduce total health-care spending by 15%. In addition, health insurance payment and medical billing processes are time-consuming and expensive for both...
The Future Priorities of the National Cancer Institute
Fifty-two years ago, President Richard Nixon signed the National Cancer Act of 1971 into law, which established the National Cancer Institute (NCI) in its current form. At the time, the budget was $1.6 billion. Today, it is $7.8 billion, $4.5 billion less than the amount needed to keep up with...
Crystal S. Denlinger, MD, FACP, Named New Chief Executive Officer of NCCN
On August 23, 2023, the National Comprehensive Cancer Network® (NCCN) announced Crystal S. Denlinger, MD, FACP, as incoming Chief Executive Officer (CEO). Dr. Denlinger, who is currently Senior Vice President and Chief Scientific Officer of NCCN, will lead the global guidelines organization...
Developing Solutions for Cancer Care Disparities Across Geography
Understanding the complexities of health disparities within cancer care requires an exploration beyond immediate clinical factors. According to Elisa Rodriguez, PhD, MS, of Roswell Park Comprehensive Cancer Center, Buffalo, New York, geography plays a critical role in defining health outcomes in...
How the Cancer Moonshot Aims to Improve the Quality of Life for Adolescent and Young Adult Cancer Survivors
Several recent studies have shown an increasingly disturbing trend: the incidence of early-onset cancers—those diagnosed in individuals younger than age 50—is on the rise, and not just in the United States but globally as well. Worldwide, in 2019, there were a reported 1.19 million new cases of...
Rapid Guideline Update Offers Key Evidence-Based Recommendations for Stage III NSCLC Management
A new ASCO guideline rapid update provides updated recommendations for the management of stage III non–small cell lung cancer (NSCLC). These updated recommendations made by the ASCO expert panel cover treatment options for patients with resected disease and specific genetic mutations as well as...
Are All Benzodiazepines Created Equal in Terms of Survival in Patients With Pancreatic Cancer?
Patients with pancreatic cancer who were treated with the benzodiazepine lorazepam had shorter progression-free survival periods than patients who were not, according to study results published by Cornwell et al in Clinical Cancer Research. In contrast, patients who were treated with the...
Is Chemotherapy Shortage Setting Back Clinical Trials?
“Any protocol that involves cisplatin or carboplatin as part of a study is on hold because of the chemotherapy shortage,” Mark J. Ratain, MD, FASCO, Chief Hospital Pharmacologist, University of Chicago Medicine, said in an interview with The ASCO Post. “Many times, our clinical trials are building...
Chemotherapy Shortage Impacts Patients, Physicians, Costs, and Clinical Trials
Grim, grimmer, and grinding are among the terms reported in the press to describe the current chemotherapy shortage.1,2 And, “it is not going away,” Mark J. Ratain, MD, FASCO, Chief Hospital Pharmacologist, University of Chicago Medicine, told The ASCO Post. “This is a progressive problem like...
New Challenge in Triple-Negative Breast Cancer: Optimizing the Sequencing of Treatments
New approaches are offering hope for better outcomes in metastatic triple-negative breast cancer, according to Suchita Pakkala, MD, of Emory University’s Winship Cancer Institute, Atlanta. She shared her thoughts on using PARP inhibitors and antibody-drug conjugates at the 2023 Debates and...
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer
The addition of the androgen receptor inhibitor darolutamide to androgen-deprivation therapy and docetaxel reduced the risk of death by 30% compared with androgen-deprivation therapy plus docetaxel in patients with metastatic hormone-sensitive prostate cancer, according to a post hoc analysis of...
Expert Point of View: Oliver Sartor, MD
The results of recent trials of PARP (poly [ADP-ribose] polymerase) inhibitor plus second-generation androgen receptor inhibitor combinations have had varying results in metastatic castration-resistant prostate cancer. Some trials suggest the benefit is confined to those with BRCA mutations and/or...
Expert Point of View: Sumanta K. Pal, MD, FASCO
“Hats off to the investigators for the first comparison of triplet to doublet in advanced renal cell carcinoma. This is also the first results using a contemporary control group. The study met its primary endpoint,” said Sumanta K. Pal, MD, FASCO, Co-Director of the Kidney Cancer Program, City of...
COSMIC-313: Triplet Therapy Is Active in Renal Cell Carcinoma, but Toxicities Pose a Challenge
The addition of cabozantinib to nivolumab plus ipilimumab prolonged progression-free survival in untreated intermediate-risk patients with advanced renal cell carcinoma (RCC), according to the first results of the phase III COSMIC-313 trial. These findings were presented as a Presidential Symposium ...
Study Shows Activity of Talquetamab in Highly Refractory Multiple Myeloma
In the phase I/II MonumenTAL-1 trial, the novel bispecific antibody talquetamab produced responses in more than 70% of heavily pretreated patients with multiple myeloma.1 Of note, the safety profile confirmed results of the phase I portion of the study (recently published in TheNew England Journal...
Expert Point of View: Ciara L. Freeman, MD, PhD and Asher Chanan-Khan, MD
Ciara L. Freeman, MD, PhD, Assistant Member, Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida, was impressed with the CARTITUDE-4 findings. She said “treaters and patients” will be “watching this space” to see how the results change the...
American Society for Radiation Oncology Names Newly Elected Officers to Board of Directors
The members of the American Society for Radiation Oncology (ASTRO) recently elected three new officers to ASTRO’s Board of Directors: Sameer Keole, MD, FASTRO, as President-Elect; Wendy Woodward, MD, PhD, FASTRO, as Science Council Vice Chair; and Vivek S. Kavadi, MD, MBA, FASTRO, as Health Policy...
Overcoming Financial Toxicity From Cancer
I knew the moment my fingers found a lump in my left breast, in 2018, that it was cancer, and I wondered if I was going to die. My maternal grandmother had been diagnosed with breast cancer when she was 39, the same age I was when I discovered the mass in my breast. She died 5 years later. Divorced ...
Susan M. Love, MD, MBA, Breast Cancer Surgeon, Researcher, and Advocate
Susan M. Love, MD, MBA, a renowned surgeon, author, researcher, and patient advocate who dedicated her life’s work to breast cancer care, died on July 2, 2023, at her home in Los Angeles. The cause of death was recurrent leukemia. She was 75. Born in Long Branch, New Jersey, on February 9, 1948,...
Alcohol Consumption and Risk of Breast Cancer Recurrence
A report published by Kwan et al in the journal Cancer provides new information that may help oncologists answer one of the most common questions they hear from breast cancer survivors: Is it safe to drink alcohol? The findings suggest drinking alcohol is not associated with an increased risk of...
On the Art of Organizing Best of ASCO Meetings
Preparing and running a medical conference is usually a complex but rewarding mission. It is a demanding job that is typically done voluntarily by physicians and educators who are dedicated to professional and community service; advancement of research and education; as well as the dissemination of ...
How Multidisciplinary Specialties Are Coming Together to Improve the Quality of Life of Cancer Survivors
As we detailed in our Special Report “Surviving, but Not Always Thriving, After Cancer,” in the May 25, 2023, issue of The ASCO Post, the combination of advances in more effective therapies to treat cancer, gains in early detection, and sharp declines in tobacco use have led to a staggering 33%...
HER2-Low Status Is ‘Dynamic’ for Patients With Triple-Negative Breast Cancer
The probability of obtaining a HER2-low test result increases with the number of biopsies performed, according to a study of more than 500 biopsy samples in patients with triple-negative breast cancer. For patients originally labeled as having no HER2 expression (HER2 0), each successive biopsy...
Report Highlights Rapid Adoption of Clinical Research Results Into Colon Cancer Chemotherapy Prescribing Patterns
New research published by Ou et al in JNCCN—Journal of the National Comprehensive Cancer Network evaluated how an important analysis on adjuvant chemotherapy for advanced colon cancer impacted prescribing patterns. The IDEA collaboration included more than 12,000 patients with stage III colon...
Researchers May Have Uncovered Two New Subtypes of HPV-Positive Head and Neck Squamous Cell Carcinomas
Human papillomavirus (HPV)–positive head and neck squamous cell carcinomas can be divided into two distinct subtypes that may help determine how well patients will respond to therapy, according to a novel study published by Schrank et al in PNAS. The findings also identified a new mechanism of HPV...
Expert Point of View: Anand Ashwin Patel, MD
As presented at the 2023 ASCO Annual Meeting, the phase III IMerge trial of imetelstat1 and the phase III COMMANDS trial of luspatercept2 met their primary endpoints of transfusion independence. The findings suggest that lower-risk patients with transfusion-dependent, non-del(5q) myelodysplastic...
IMerge Trial: Use of Imetelstat Reduces Transfusion Dependence in Lower-Risk MDS
In the primary analysis of the phase III randomized, double-blind, placebo-controlled IMerge trial, in those achieving the primary endpoint of 8-week transfusion independence, treatment with imetelstat significantly reduced transfusion dependence—for a median duration of 1 year—and improved a...
Forced Displacement and Diagnosis of Cancer in Syrian Refugees
Syrian migrants, including refugees, may be more likely to be diagnosed with a more advanced stage of breast cancer at a younger age when compared with individuals from Jordan, according to a recent study published by Hazra et al in JAMA Network Open. The new findings suggest the trauma associated...
Keeping Staff and Patients Safe From Workplace Violence
The statistics are chilling. According to estimates from the U.S. Bureau of Labor Statistics, workers in the fields of health care and social services are five times more likely to suffer from a workplace violence injury than workers overall.1 The Bureau statistics show that the rate of injuries...
‘I Want to Kill You’
My patient threatened to kill me. I was in the middle of a busy medical oncology clinic. I was seeing her to discuss test results 1 week after I told her I was concerned that her cancer had returned. As I suspected, the test confirmed recurrent cancer, and this time, it was incurable. I walked into ...
Roundup of Abstracts on New Therapies for Gastrointestinal Cancers From ASCO 2023
The 2023 ASCO Annual Meeting featured thousands of abstracts. In addition to our in-depth coverage of pivotal research from the meeting, The ASCO Post highlights the following studies of novel therapies for gastrointestinal cancers. Addition of Anti-TIGIT Agent in Unresectable Liver Cancer In the...
CLL14: Long-Term Results of Fixed-Duration Venetoclax Plus Obinutuzumab in Elderly Patients With CLL
The 6-year follow-up of a landmark study has revealed significant treatment-free remissions and safety findings in elderly patients with chronic lymphocytic leukemia (CLL) and coexisting medical conditions.1 Long-term results of the CLL14 trial, presented during the European Hematology Association...
EBCTCG Meta-analysis Confirms Benefit of Ovarian Ablation or Suppression in Preventing Breast Cancer Recurrence
A meta-analysis of randomized trials has revealed a benefit to ovarian ablation or suppression in preventing breast cancer recurrence in premenopausal women with estrogen receptor–positive tumors.1 The findings, based on almost 15,000 women in studies spanning several decades, were presented at the ...
Psilocybin and Other Psychedelics May Help Patients With Late-Stage Gynecologic Cancer Tackle Mental Health Symptoms
Investigators revealed that psilocybin-assisted psychotherapy and other psychedelics may effectively ease symptoms of anxiety and depression in patients with late-stage gynecologic cancers, according to a new commentary published by Yaniv et al in the International Journal of Gynecological Cancer. ...
Diversity May Play a Key Role in Black Patients’ Trust of Videos About Prostate Cancer
Black patients may be 1.6 times more likely to believe medical information presented by a Black speaker than information presented by a White speaker, according to a new study published by Loeb et al in JAMA Network Open. The findings highlight the importance of increasing racial diversity among...
Alfredo Quiñones-Hinojosa, MD: From Migrant Farm Worker to Neurosurgeon in Search of a Cure for Brain Cancer
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with neurosurgeon Alfredo Quiñones-Hinojosa, MD, FAANS, FACS, the James C. and Sarah K. Kennedy Dean of Research, Monica Flynn Jacoby Chair of Neurologic Surgery, and William J. and Charles...
WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Drs. Syed Ali Abutalib and L. Jeffrey Medeiros explore the World Health Organization (WHO) classification of hematopoietic and lymphoid tissue...
In Ovarian Cancer, Neoadjuvant Olaparib Feasible, Appears Effective in Pilot Study Among Patients With BRCA Mutation
Encouraging outcomes were achieved in patients with BRCA-mutated ovarian cancer who received neoadjuvant treatment with olaparib in a feasibility study led by Shannon N. Westin, MD, MPH, Professor in the Department of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD...
APOBEC3A Protein May Be Linked to Drug Resistance in Patients With NSCLC
Researchers have uncovered how non–small cell lung cancer (NSCLC) tumors may develop drug resistance over time and identified the APOBEC3A protein as a potential target for novel cancer therapeutics, according to a study published by Isozaki et al in Nature. The findings point to potential...
Front-Line Treatment of Advanced Renal Cell Carcinoma
This is Part 2 of Treatment Considerations in Renal Cell Carcinoma, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Brian Rini, Pedro Barata, and Kathryn Beckermann discuss the front-line treatment of advanced renal cell...
PHERGain: Adapted-Response Trial Guides Treatment With Dual HER2 Blockade Alone
The phase II PHERGain trial, which employed a response-adapted strategy in the treatment of early-stage, HER2-positive breast cancer, has shown promising results for the selective use of HER2 blockade and de-escalation of chemotherapy.1 Nearly all patients assigned to skip chemotherapy prior to...
Changing How Immune Checkpoint Inhibitors Are Delivered Could Reduce Costs by 14%, Study Finds
Investigators have found that millions of dollars could be saved annually across the Veterans Health Administration by reconsidering how immune checkpoint inhibitors are delivered, according to a new study published by Bryant et al in Health Affairs. The findings suggested that if vials of immune...
Expert Point of View: Erminia Massarelli, MD, PhD, MS
The invited discussant of the VERSATILE-002 and CUE-101-01 trials, Erminia Massarelli, MD, PhD, MS, said both are examples of a growing interest in evaluating immunotherapeutic strategies and treatment sequences in early-stage head and neck squamous cell cancer as well as in metastatic disease. Dr. ...
I Didn’t Want My Past to Become My Future
When I felt a large mass in my left breast as I was drying off from a shower on Thanksgiving Day, in 2007, I instinctively knew it was cancer. My mother had been diagnosed with breast cancer when she was 38, just 7 years older than I was at the time, and died 4 years later. I was 6 when she was...
